Insider Trade Allegations Hit Korea Biosimilars Leader Celltrion
This article was originally published in PharmAsia News
Executive Summary
Celltrion’s shares closed down 5.4% Sept. 16 following reports in local media that company management met with regulators on Friday to reject allegations of leaking undisclosed material information to certain investors.